Summary: Researchers unmasked a critical behavioral paradox in modern weight management, proving that adults utilizing glucagon-like peptide-1 (GLP-1) receptor agonists experience a significant, measurable decline in daily physical activity.
Utilizing un-coerced wearable sensor tracking data from the National Institutes of Health (NIH) All of Us Research Program, the team analyzed Fitbit activity records alongside electronic health records of adults managing obesity.
The findings revealed that instead of naturally moving more as they shed weight, patients experienced a sharp drop in both daily step counts and moderate-to-vigorous physical activity (MVPA) minutes, creating a severe physiological risk given that exercise is mandatory to protect critical lean muscle tissue during rapid weight loss.
Key Facts
- Dismantling the Activity Assumption: Clinical medicine has long assumed that significant weight loss naturally triggers an automatic, spontaneous increase in a patient’s physical activity. This large-scale tracking trial formally disproves that assumption, revealing that metabolic weight loss actually correlates with reduced daily movement.
- The Threat to Lean Muscle Mass: GLP-1 receptor agonists like semaglutide, liraglutide, dulaglutide, and tirzepatide do not selectively target fat tissue alone; they also reduce vital lean muscle mass. This reality makes targeted, consistent resistance training and physical activity mandatory to preserve strength and protect long-term metabolic healthspan.
- Leveraging Real-World Fitness Trackers: This project represents the first major medical study to analyze continuous, real-world data from wearable fitness trackers among a large cohort of adults taking GLP-1 receptor agonists, shifting away from notoriously unreliable patient-completed exercise journals.
- Quantifying the Exercise Deficit: The data revealed a substantial drop in physical output across the board. On average, participants saw their daily step counts drop from 5,047 down to 4,487 steps per day, while their high-value moderate-to-vigorous physical activity (MVPA) fell from 28 down to just 22 minutes per day.
- Identifying High-Risk Drop Off Zones: While variables like chronological age, chronic heart failure, or a history of stroke did not alter the downward exercise trend, the sharpest physical activity declines were isolated in male participants and in individuals battling pre-existing joint or muscle pain.
- Robust Multi-Center Cohort Metrics: The retrospective pre-post study design filtered data from 1,950 adults within the NIH database who initiated GLP-1 therapy. The team isolated 753 individuals who possessed comprehensive, long-term wearable device data for high-fidelity analysis, yielding a cohort that was 78.6% female with a mean age of 52.7 years.
- A Mandate for Targeted Clinical Interventions: Dr. Maharjan emphasizes that these findings demand a major evolution in how anti-obesity drugs are prescribed. Because exercise cannot be treated as an optional lifestyle recommendation, future weight loss protocols must pair the medication with structured behavioral interventions to enforce muscle-preserving movement.
Source: Endocrine Society
Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill.
GLP-1 receptor agonists like semaglutide, liraglutide, dulaglutide and tirzepatide reduce not only fat but also lean muscle mass. This makes physical activity essential for preserving strength and long-term health, according to study lead Sajana Maharjan, M.D., of HSHS St. John’s Hospital in Springfield, Ill.
The retrospective pre–post cohort study used data from the National Institutes of Health’s All of Us Research Program, which links participants’ electronic health records with their Fitbit activity data. Among the 1,950 adults with obesity who started a GLP-1 medication, researchers studied 753 people who had enough wearable-device data for analysis. The cohort was predominantly female (78.6%) with a mean age of 52.7 years.
Researchers compared each person’s physical activity before and after starting treatment, focusing on daily step counts and moderate-to-vigorous physical activity (MVPA) minutes.
On average, daily steps decreased from 5,047 to 4,487 steps per day, and MVPA minutes fell from 28 to 22 per day after beginning a GLP-1 receptor agonist medication. The largest declines were seen in men and in people with joint or muscle pain, while factors such as age, heart failure or prior stroke did not change the results. The study found no evidence that weight loss from these medications led to increased physical activity.
“While many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise. The findings in our study reinforce that exercise cannot be optional for people taking these medications. People need targeted interventions that encourage physical activity alongside medication for obesity,” Maharjan said.
This is the first large study analyzing data from wearable fitness trackers among adults taking GLP-1 receptor agonists.
Key Questions Answered:
A: While common sense suggests that a lighter body should make physical movement easier and more appealing, the data proves that weight loss from these medications does not naturally boost physical activity. The underlying cause may stem from the profound ways these drugs alter systemic energy balance, appetite signals, and central nervous system pathways. Additionally, because these medications rapidly reduce total caloric intake, users might experience subtle drops in spontaneous daily energy expenditure and movement.
A: Because rapid weight loss from GLP-1 receptor agonists strips away critical lean muscle mass alongside body fat. Muscle tissue is the main engine of your resting metabolism, physical strength, and glucose regulation. If a patient experiences a significant drop in physical activity while taking these drugs, they will lose an alarming amount of muscle texture. This can leave them physically weaker, compromise their joint stability, and trigger long-term metabolic issues once they stop taking the medication.
A: By ending the practice of prescribing these drugs as a standalone monotherapy. This ENDO 2026 study proves that doctors cannot simply assume their patients will start working out once they lose weight. Medical providers must treat structured exercise as a non-negotiable part of the prescription. Clinics should implement targeted behavioral interventions, remote wearable tracking monitors, and mandatory resistance training programs from day one to actively protect muscle architecture during weight loss.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this exercise and GLP-1 research news
Author: Jenni Gingery
Source: Endocrine Society
Contact: Jenni Gingery – Endocrine Society
Image: The image is credited to Neuroscience News
Original Research: The findings will be presented at ENDO 2026
